{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:44:48Z","timestamp":1771461888804,"version":"3.50.1"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T00:00:00Z","timestamp":1660521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Despite scientific and clinical advances during the last 50 years cardiovascular disease continues to be the main cause of death worldwide. Especially patients with diabetes display a massive increased cardiovascular risk compared to patients without diabetes. Over the last two decades we have learned that cardiometabolic and cardiovascular diseases are driven by inflammation. Despite the fact that the gastrointestinal tract is one of the largest leukocyte reservoirs of our bodies, the relevance of gut immune cells for cardiovascular disease is largely unknown. First experimental evidence suggests an important relevance of immune cells in the intestinal tract for the development of metabolic and cardiovascular disease in mice. Mice specifically lacking gut immune cells are protected against obesity, diabetes, hypertension and atherosclerosis. Importantly antibody mediated inhibition of leukocyte homing into the gut showed similar protective metabolic and cardiovascular effects. Targeting gut immune cells might open novel therapeutic approaches for the treatment of cardiometabolic and cardiovascular diseases.<\/jats:p>","DOI":"10.3389\/fcvm.2022.943214","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T06:40:12Z","timestamp":1660545612000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Gut immune cells\u2014A novel therapeutical target for cardiovascular disease?"],"prefix":"10.3389","volume":"9","author":[{"given":"Naresh","family":"Ganesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiel P. C.","family":"van der Vorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Spiessh\u00f6fer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Burgmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannes","family":"Findeisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lehrke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip K.","family":"Swirski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Kahles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMra1112570","article-title":"A tale of coronary artery disease and myocardial infarction","volume":"366","author":"Nabel","year":"2012","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"385","year":"2015","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2013an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","article-title":"Transatlantic network on, inflammation in atherosclerosis: from pathophysiology to practice","volume":"54","author":"Libby","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1126\/science.1230719","article-title":"Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure","volume":"339","author":"Swirski","year":"2013","journal-title":"Science."},{"key":"B13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nature11260","article-title":"Myocardial infarction accelerates atherosclerosis","volume":"487","author":"Dutta","year":"2012","journal-title":"Nature."},{"key":"B14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41590-022-01165-7","article-title":"B lymphocyte-derived acetylcholine limits steady-state and emergency hematopoiesis","volume":"23","author":"Schloss","year":"2022","journal-title":"Nat Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0735-1097(02)02484-1","article-title":"Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy- thrombolysis in myocardial infarction 18 trial) substudy","volume":"40","author":"Sabatine","year":"2002","journal-title":"J Am Coll Cardiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1001\/jama.257.17.2318","article-title":"Leukocytes and the risk of ischemic diseases","volume":"257","author":"Ernst","year":"1987","journal-title":"JAMA."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"H1227","DOI":"10.1152\/ajpheart.00612.2020","article-title":"Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease","volume":"319","author":"Lewis","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/microorganisms10010108","article-title":"Gut dysbiosis and immune system in atherosclerotic cardiovascular disease (ACVD)","volume":"10","author":"Yoo","year":"2022","journal-title":"Microorganisms."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1253\/circj.CJ-15-0526","article-title":"Intestinal immunity and gut microbiota as therapeutic targets for preventing atherosclerotic cardiovascular diseases","volume":"79","author":"Yamashita","year":"2015","journal-title":"Circ J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1600-065X.1997.tb00966.x","article-title":"The anatomical basis of intestinal immunity","volume":"156","author":"Mowat","year":"1997","journal-title":"Immunol Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1084\/jem.161.3.475","article-title":"Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4\/80","volume":"161","author":"Lee","year":"1985","journal-title":"J Exp Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0889-8553(21)00570-7","article-title":"Intestinal intraepithelial lymphocytes","volume":"20","author":"Cerf-Bensussan","year":"1991","journal-title":"Gastroenterol Clin North Am."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1073\/pnas.89.5.1924","article-title":"A family of beta 7 integrins on human mucosal lymphocytes","volume":"89","author":"Parker","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/j.1460-2075.1989.tb03566.x","article-title":"Peyer's patch-specific lymphocyte homing receptors consist of a VLA-4-like alpha chain associated with either of two integrin beta chains, one of which is novel","volume":"8","author":"Holzmann","year":"1989","journal-title":"EMBO J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/0092-8674(89)90981-1","article-title":"Identification of a murine Peyer's patch\u2013specific lymphocyte homing receptor as an integrin molecule with an alpha chain homologous to human VLA-4 alpha","volume":"56","author":"Holzmann","year":"1989","journal-title":"Cell."},{"key":"B30","doi-asserted-by":"publisher","first-page":"836","DOI":"10.2174\/156652409789105525","article-title":"Role of beta7 integrins in intestinal lymphocyte homing and retention","volume":"9","author":"Gorfu","year":"2009","journal-title":"Curr Mol Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nri3007","article-title":"The light and dark sides of intestinal intraepithelial lymphocytes","volume":"11","author":"Cheroutre","year":"2011","journal-title":"Nat Rev Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-018-0849-9","article-title":"Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease","volume":"566","author":"He","year":"2019","journal-title":"Nature."},{"key":"B33","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cmet.2015.05.020","article-title":"Jejunal T cell inflammation in human obesity correlates with decreased enterocyte insulin signaling","volume":"22","author":"Monteiro-Sepulveda","year":"2015","journal-title":"Cell Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1172\/JCI78941","article-title":"Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients","volume":"125","author":"Magalhaes","year":"2015","journal-title":"J Clin Invest."},{"key":"B35","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cmet.2015.03.001","article-title":"Regulation of obesity-related insulin resistance with gut anti-inflammatory agents","volume":"21","author":"Luck","year":"2015","journal-title":"Cell Metab."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e0122195","DOI":"10.1371\/journal.pone.0122195","article-title":"High fat diet causes depletion of intestinal eosinophils associated with intestinal permeability","volume":"10","author":"Johnson","year":"2015","journal-title":"PLoS ONE."},{"key":"B37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cmet.2015.06.001","article-title":"The gut microbiota regulates intestinal CD4 T cells expressing RORgammat and controls metabolic disease","volume":"22","author":"Garidou","year":"2015","journal-title":"Cell Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1172\/JCI88879","article-title":"Immunologic impact of the intestine in metabolic disease","volume":"127","author":"Winer","year":"2017","journal-title":"J Clin Invest."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1038\/s41467-019-11370-y","article-title":"Gut-associated IgA(+) immune cells regulate obesity-related insulin resistance","volume":"10","author":"Luck","year":"2019","journal-title":"Nat Commun."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1038\/s41467-021-22727-7","article-title":"Emerging concepts in intestinal immune control of obesity-related metabolic disease","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology."},{"key":"B42","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/MOL.0b013e328359b19f","article-title":"New antidiabetic therapies: innovative strategies for an old problem","volume":"23","author":"Lehrke","year":"2012","journal-title":"Curr Opin Lipidol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet."},{"key":"B48","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1038\/nm.2513","article-title":"Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells","volume":"17","author":"Ellingsgaard","year":"2011","journal-title":"Nat Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.2337\/db14-0100","article-title":"GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering","volume":"63","author":"Kahles","year":"2014","journal-title":"Diabetes."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1111\/dom.13472","article-title":"Myocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacity","volume":"20","author":"Diebold","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"B53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1475-2840-12-117","article-title":"Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans","volume":"12","author":"Piotrowski","year":"2013","journal-title":"Cardiovasc Diabetol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e003201","DOI":"10.1136\/bmjopen-2013-003201","article-title":"Elevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction: a cross-sectional study","volume":"3","author":"Hattori","year":"2013","journal-title":"BMJ Open."},{"key":"B55","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.amjmed.2017.03.010","article-title":"GLP-1 levels predict mortality in patients with critical illness as well as end-stage renal disease","volume":"130","author":"Lebherz","year":"2017","journal-title":"Am J Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/eurheartj\/ehz728","article-title":"Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction","volume":"41","author":"Kahles","year":"2019","journal-title":"Eur Heart J."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2337\/db14-1577","article-title":"GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R","volume":"64","author":"Yusta","year":"2015","journal-title":"Diabetes."},{"key":"B58","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0140-6736(17)30930-3","article-title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"390","author":"Vermeire","year":"2017","journal-title":"Lancet."},{"key":"B59","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/14712598.2020.1691520","article-title":"Anti-MADCAM therapy for ulcerative colitis","volume":"20","author":"Picardo","year":"2020","journal-title":"Expert Opin Biol Ther."},{"key":"B60","doi-asserted-by":"publisher","first-page":"P128","DOI":"10.1016\/S2468-1253(21)00298-3","article-title":"Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial","volume":"7","author":"Peyrin-Biroulet","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.943214\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T06:40:16Z","timestamp":1660545616000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.943214\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":61,"alternative-id":["10.3389\/fcvm.2022.943214"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.943214","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]},"article-number":"943214"}}